No need for broad-spectrum empirical antibiotic coverage after surgical drainage of orthopaedic implant infections by Schindler, Maximilian et al.
ORIGINAL PAPER
No need for broad-spectrum empirical antibiotic coverage
after surgical drainage of orthopaedic implant infections
Maximilian Schindler & Axel Gamulin & Wilson Belaieff &
Maruschka Francescato & Alexis Bonvin & Véronique Graf &
Pierre Hoffmeyer & Blaise Wyssa & Ilker Uçkay
Received: 20 March 2013 /Accepted: 28 April 2013 /Published online: 7 June 2013
# Springer-Verlag Berlin Heidelberg 2013
Abstract
Purpose Empirical broad-spectrum antibiotic treatment for
orthopaedic implant infections after surgical lavage is com-
mon practice while awaiting microbiological results, but
lacks evidence.
Methods This was a single-centre cohort study from 1996 to
2010 with a follow-up of two years.
Results We retrieved 342 implant infections and followed
them up for a median of 3.5 years (61 recurred, 18 %).
Infected implants were arthroplasties (n=186), different
plates, nails or other osteosyntheses. The main pathogens
were S. aureus (163, 49 methicillin-resistant) and coagulase-
negative staphylococci (60, 45 methicillin-resistant). Median
duration of empirical antibiotic coverage after surgical drain-
age was three days before switching to targeted therapy.
Vancomycin was the most frequent initial empirical agent
(147), followed by intravenous co-amoxiclav (44). Most em-
pirical antibiotic regimens (269, 79 %) proved sensitive to the
causative pathogen, but were too broad in 111 episodes
(32 %). Cephalosporins and penicillins were used only in 44
and ten cases, respectively, although they would have covered
59 % of causative pathogens identified later. Multivariate Cox
regression analysis showed that neither susceptible antibiotic
coverage (compared to non-susceptible; hazard ratio 0.7,
95 % confidence interval 0.4–1.2) nor broad-spectrum use
(hazard ratio 1.1, 0.8–1.5) changed remission rates.
Conclusions Provided that surgical drainage is performed,
broad-spectrum antibiotic coverage does not enhance remis-
sion of orthopaedic implant infections during the first
three days. If empirical agents are prescribed from the first
day of infection, narrow-spectrum penicillins or cephalospo-
rins can be considered to avoid unnecessary broad-spectrum
antibiotic use.
Introduction
During debridement and/or removal of infected implants,
orthopaedic surgeons perform intraoperative microbiological
sampling and start empirical antibiotic therapy. Because the
pathogen is often unknown at debridement and due to doubts
of polymicrobial and resistant nosocomial infections, this
initial coverage is usually too large in the antibiotic spectrum.
Sometimes, also the local epidemiology with potentially
resistant germs determines the choice of empirical antimicro-
bial therapy and not only the desire to cover all pathogens.
However, existing recommendations and guidelines address
choices and durations of targeted antibiotic therapy [1, 2], but
do not propose initial empirical coverage, which is left to the
discretion of the treating surgeon [3]. Many colleagues think
that it would be beneficial if empirical antibiotic administra-
tion could cover all possible pathogens for arthroplasty [2] and
other orthopaedic infections [4], with usual recurrence rates
oscillating between 15 and 28 % [2, 5, 6], and especially in
cases of implant retention. Experimentally speaking, biofilms
are established within a few hours or days [7], and infections
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with resistant micro-organisms may harbour more treat-
ment failures than infections due to susceptible bacteria [5].
Therefore it is not surprising that many authors routinely admin-
ister vancomycin, alone [3] or in combination with meropenem
[2, 3], or aminoglycosides [4] or other antipseudomonal drugs
[4], until the pathogen is identified.
However, antibiotic excesses, even of short duration,
contribute to the spread of multi-resistant pathogens [8, 9]
and might harm the patient, e.g. antibiotic-related diarrhoea in
its multiple forms [2]. The prolongation of antibiotic adminis-
tration beyond 24 hours after surgery favours the acquisition of
antibiotic resistance, particularly among Gram-negative path-
ogens [9], which may become responsible for epidemics in
septic orthopaedic wards.
In this study, we postulate that surgical drainage is the
most important therapeutic action, while the antibiotic cov-
erage during the initial days does not influence outcome.
Methods
Geneva University Hospitals serve as a 2,000-bed tertiary
teaching hospital and the only public health institution in the
canton (county). The Orthopedic Service has 132 beds and has
conducted an arthroplasty cohort since 1996, together with
several prospective databases regarding orthopaedic infec-
tions. Patients are followed up after hospital discharge until
remission of infection. Arthroplasty patients are followed up
at one year and five years, even in the absence of problems.
Data collection and definitions
MS and IU retrospectively collected 61 variables of ortho-
paedic implant infections in adults from January 1996 to
December 2010. The last day of active follow-up was 31
December 2012. We excluded recurrent episodes, paediatric
cases, patients in the intensive care units and those that had
been treated by antibiotics before admission [10]. The diag-
nosis of implant infection was based upon the presence of
intraoperative pus together with clinical signs of infection
(new onset of pain, fever, sinus tract, discharge) and/or
radiographic signs of implant loosening. Species identifica-
tion required the same pathogen to be present in at least two
intraoperative samples [11]. This study is about the active
spectrum of prescribed antibiotic agents. For our study, we
defined what we considered as adequate and what spectrum
was too broad for the individual pathogen. In the literature,
there is only flawed consensus on what is regarded as “too
broad” and what is not, depending on the local medical culture.
Empirical antibiotic treatment was considered too broad when
the applied agent exceeded the minimum applicable spectrum
defined as the use of penicillin, amoxicillin, cefuroxime,
cefamandole, clindamycin, co-trimoxazole, flucloxacillin and
depending on the pathogen. These agents cover most of the
Gram-positive pathogens, the hallmark of orthopaedic infec-
tions. By study definition, broad-spectrum antibiotic therapy
covered more than necessary. Consequently, co-amoxiclav,
ceftriaxone, ceftazidime, cefepime, piperacillin/tazobactam,
carbapenems, quinolones, daptomycin, linezolid, tigecycline,
systemic or local aminoglycosides or glycopeptides were con-
sidered too broad if the pathogen was susceptible to narrow-
spectrum coverage. In contrast, it was considered adequate if
the bacteria were resistant, leaving no choice for a narrower
spectrum.
Statistical analyses
Group comparisons were performed using the Pearson’s χ2 or
the Wilcoxon rank sum test, as appropriate. A Cox regression
analysis determined association with outcome remission.
Only first episodes of implant infections were included.
Independent variables with a p value ≤0.2 in univariate anal-
ysis were introduced stepwise in the multivariate analysis
[12]. Key variables regarding antibiotic coverage were intro-
duced into the final model independently of univariate results.
All variables were checked for confounding and interaction:
the latter by interaction terms and Mantel-Haenszel estimates.
A p value ≤0.05 (two-tailed) was significant. Stata™ software
(9.0, StataCorp, College Station, TX, USA) was used.
Results
Patients and infections
A total of 342 infections in 342 patients (133 women) met
the study criteria and were actively followed up for a median
of 3.5 years (range, two to 15 years). The median age was
67 years (range 18–94 years) and 109 patients (32 %) were
immunocompromised due to diabetes mellitus (n=41), ac-
tive cancer (25), severe alcoholism (16), steroid medication
(13), Child’s class C cirrhosis (4), uncontrolled human im-
munodeficiency virus (HIV) disease (2), splenectomy (1),
dialysis (1) and and organ transplantation (1). Six patients
suffered from combinations.
The infected implants were 113 hip arthroplasties, 68
knee arthroplasties, two ankle prostheses, one shoulder
prosthesis, one elbow prosthesis and one unicompartmental
knee implant. The remaining 156 (46 %) infected implants
were dynamic hip screws, plates, screws, nails and external
fixations in various bones. Pathogens varied considerably.
We found 36 different monomicrobial and 18 polymicrobial
episodes [11]. Sonication was not performed. The main
germ was methicillin-sensitive Staphylococcus aureus
(114, 33 %), followed by coagulase-negative staphylococci
(60, 17 %) and methicillin-resistant S. aureus (MRSA; 49,
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14 %). Enterococci were encountered in seven infections.
Gram-negative infections were a minority (51, 15 %), in-
cluding 18 episodes due to Pseudomonas spp., 11 other non-
fermenting rods and two extended-spectrum beta-lactamase
producers. Strict anaerobes were detected in five cases,
three of which were co-pathogens. Overall, 75 episodes were
bacteraemic without haemodynamically compromising sepsis.
Antibiotic treatment
The median duration of empirical treatment was three days
(range 0–18 days). Overall, single-agent use (246) was more
frequent than combination therapy (67). The most frequent
agent used was vancomycin (n=147), solely (89) or in com-
bination. Other empirical antibiotics were co-amoxiclav (44
episodes), quinolones (23), flucloxacillin (21), aminoglyco-
sides (18), carbapenems (15), cefepime (15), ceftriaxone
(10), clindamycin (13) and piperacillin/tazobactam (2).
Co-trimoxazole, daptomycin, fusidic acid, metronidazole,
teicoplanin and ceftazidime were mostly co-administered with
other antimicrobials in less than three cases each.
The majority of antibiotic regimens (269/342, 79 %)
proved to be sensitive to the later identified pathogen, but
was too broad in 111 cases (32 %). Of note, 29 patients
(8 %) did not receive any empirical treatment, because
infection was diagnosed only when intraoperative speci-
mens became positive. Anaerobic coverage with mostly
amoxicillin/clavulanate or clindamycin was performed in
130 episodes (38 %), although only three pathogens were real
strict anaerobes, while we could not elucidate why exactly the
treating physicians chose agents with concomitant anaerobic
coverage. Penicillin (including amoxicillin) and first- and
second-generation cephalosporins were used in ten and 44
cases, respectively, although they would have covered 59 %
of all later identified pathogens. Once the pathogen was iden-
tified, the overall median duration of targeted antimicrobial
therapy was 56 days (range 14–294 days), of which a median
of 14 days intravenously (range 0–100 days).
Surgical treatment
Surgery was part of treatment for every episode with a mean
and median number of two interventions (range 0–17). The
number of surgical interventions between episodes with
broad-spectrum compared to narrow-spectrum coverage
was similar (median two vs two interventions, p=0.77). In
86 episodes (25 %), the infected implant was retained.
Among the 186 arthroplasty infections, 86 (46 %) were
treated with debridement and retention alone, 7 (4 %) were
removed without further implantation and 91 (49 %) epi-
sodes underwent a two-stage exchange with a median inter-
val of nine weeks between the two stages. Only two one-
stage arthroplasty exchanges were performed.
Outcomes and multivariate analysis
Among all 342 episodes of implant infections, 61 (18 %)
clinically recurred after a median of 5.5 months with iden-
tical pathogens. The patient populations with and without
recurrences were similar with the exception of arthroplasty
retention and immunosuppression (Table 1). Because of a
substantial variety of pathogens, antibiotics and implants,
we performed a Cox regression analysis to adjust for case
mix (Table 2). In multivariate analysis, no variable was
associated with recurrence. Adequate choice of empirical
drugs [hazard ratio (HR) 0.7, 95 % confidence interval
(CI) 0.4–1.2] [reciprocal: wrong antibiotic coverage (HR
1.1, 0.8–1.5)], broad-spectrum coverage (HR 1.1, 0.8–1.5)
or duration of vancomycin use (HR 1.0, 1.0–1.0) failed to
enhance remission. Of note, the receiver-operating charac-
teristic curve value was 0.80, highlighting an acceptable
accuracy of our final model.
Discussion
Among 342 adult patients with implant infections, one fifth
underwent an empirical antibiotic treatment post-drainage
that did not cover the later identified pathogen, and one third
witnessed excessive coverage in our retrospective evalua-
tion of daily clinical practice. However, broad-spectrum
antibiotic coverage failed to enhance remission or to reduce
the number of surgical interventions. Equally, empirical use
of vancomycin showed no protective effect, although in our
institution the MRSA endemicity among clinical S. aureus
isolates is around 28 % [13] and 75 % of clinical coagulase-
negative staphylococci are methicillin-resistant [14]. At the
same time, we failed to prove any inconvenience for the
episodes where empirical therapy was wrongly chosen dur-
ing the first three days.
Many patients witnessed treatment against anaerobes,
although finally there were only five anaerobic (co)-patho-
gens detected. Regarding this anaerobic coverage, we could
not detect why the treating surgeons and physicians chose
antimicrobial agents active against anaerobic pathogens.
Retrospectively, narrow-spectrum penicillins or second-
generation cephalosporins alone would have correctly cov-
ered two thirds of the pathogens.
We would discourage the use of routine empirical van-
comycin coverage. Our opinion is in line with experts de-
nying the existence of a threshold of resistant staphylococcal
surgical site infections [13, 14], above which a switch to
glycopeptides would be necessary in terms of prevention
and empirical treatment [8, 15]. Authors from the Mayo
Clinic successfully treated culture-negative prosthetic joint
infections throughout the course with cefazolin alone, with
no excess of treatment failure (HR 0.7, 95 % CI 0.2–3.0)
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Table 1 Comparison of episodes with and without recurrence of implant infections
Numbers,
n=342
Recurrence,
n=61
pa Remission,
n=281
Female gender 133 19 (31 %) 114 (41 %)
Median age 64 years 67 years
Immunosuppressionb 109 26 (43 %) 0.047 83 (30 %)
Arthroplasty infection 186 31 (51 %) 155 (55 %)
Retained arthroplasties 86 20 (33 %) 0.042 66 (24 %)
Two-stage exchanges 91 11 (18 %) 80 (28 %)
Bacteraemia 75 14 (23 %) 61 (22 %)
MRSA infectionc 49 11 (18 %) 38 (14 %)
Gram-negative infection 51 10 (16 %) 41 (15 %)
Empirical vancomycin use 147 28 (46 %) 119 (42 %)
Correct empirical antibiotic coverage 269 44 (72 %) 225 (80 %)
Too broad spectrum use 111 21 (34 %) 90 (32 %)
Median duration of empirical antibiotics 3 days 3 days
Median duration of total antibiotic use 60 days 56 days
Median duration of IV antibiotics 14 days 14 days
Median no. of surgical interventions 2 interventions 2 interventions
a Pearson’s χ2 test. Only significant values (p value <0.05) are displayed
b diabetes, cancer, alcoholism, steroid medication, cirrhosis, HIV, splenectomy, dialysis
cMethicillin-resistant Staphylococcus aureus
Table 2 Cox regression analysis
with outcome remission of or-
thopaedic implant infections
n.a. omitted from final model
because of interaction or limited
number of variables
aDiabetes, cancer, alcoholism,
steroid medication, cirrhosis,
HIV, splenectomy, dialysis
bMethicillin-resistant
Staphylococcus aureus
Variable Univariate analysis Multivariate analysis
HR, 95 % CI HR, 95 % CI
Female gender 1.0, 0.8–1.3 n.a.
Age 1.0, 1.0–1.0 n.a.
Age 65 years compared to < 65 years 1.1, 0.9–1.4 n.a.
Arthroplasty infection 1.0, 0.8–1.3 n.a.
Arthroplasty retention 1.2, 0.8–1.7 n.a.
Two-stage exchanges 0.8, 0.5–1.04 n.a.
All implant retentions 1.2, 0.9–1.6 1.4, 0.8–2.3
Immunosuppressiona 1.1, 0.8–1.4 1.4, 0.9–2.2
MRSA infectionb 1.1, 0.8–1.5 n.a.
Gram-negative infection 1.3, 0.9–1.8 n.a.
Due to Pseudomonas spp. 1.3, 0.8–2.2 n.a.
Polymicrobial infection 1.2, 0.7–2.3 n.a.
No. of surgical interventions 1.0, 0.9–1.1 1.0, 0.9–1.1
Antibiotic-related parameters
Empirical vancomycin use 1.2, 0.9–1.5 n.a.
Duration of vancomycin use 1.0, 1.0–1.0 1.0, 1.0–1.0
Correct empirical coverage 0.8, 0.6–1.1 0.7, 0.4–1.2
(Wrong empirical coverage) 1.2, 0.9–1.6 1.1, 0.8–1.5)
Too broad spectrum use 1.2, 0.9–1.5 1.1, 0.8–1.5
Duration of empirical antibiotics 1.0, 0.9–1.1 1.0, 0.9–1.1
Duration of total antibiotic use 1.0, 1.0–1.0 n.a.
6–12 weeks compared to < 6 weeks 1.1, 0.9–1.5 1.1, 0.7–1.7
>12 weeks compared to < 6 weeks 1.1, 0.8–1.5 1.1, 0.7–2.0
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[17]. Despite widespread practice and recommendations,
few studies scientifically advocate universal empirical van-
comycin use after lavage. However, they may stem from
institutions where the proportion of MRSA infections was
64 %, compared to 14 % in our study [3].
One theoretical concern of our study relates to retained
implants, especially retained arthroplasties. Biofilm formation
starts within a very short period of time [7]. If an implant is
removed (and therefore the biofilm is removed with the im-
plant), it is conceivable that potentially incorrect antibiotic
therapy has no influence on the outcome. In contrast, it might
be difficult to understand why an inadequate empirical antibi-
otic therapy has no influence on treatment failure when the
attached implant has not been removed, as we show in this
study.
For us, this discrepancy between theoretical concern and
practice is not surprising for various reasons. First, empirical
antibiotic coverage only lasted for the first three days (e.g.
7 % of the total duration), and not the rest of the antibiotic
prescription (93 %). Second, even if the prosthesis was
retained, the patient underwent at least one thorough
debridement, which is more important in mechanically re-
moving the biofilm than the chemical effect of antibiotic
drugs, which combat bacteria but not the matrix of the
biofilm per se. Finally, biofilm formation within hours is
supported by in vitro data, but no one knows the time delay
above which this biofilm becomes clinically decisive. In the
literature, some groups of expert researchers advocate that, in
vitro, biofilms are established rapidly, but in vivo, they still
allow clinicians to retain the prosthesis up to three weeks
after the onset of infection [1, 17].
In conclusion, we think the most important part in the
treatment of orthopaedic implant infections is surgical drain-
age, long before antibiotics show benefit. The effect of this
initial lavage is substantial, reducing microbial inoculum and
removing pus, independently of whether or not the implant
has been retained. Penicillins or cephalosporins might be
sufficient to bridge the short time until availability of micro-
biological results, even if this narrow spectrum does not
cover the pathogen. We therefore discourage the use of
routine empirical vancomycin or other broad-spectrum cov-
erage, unless the local epidemiology is unusual or there is
currently an outbreak situation due to resistant pathogens.
If future prospective trials confirm our findings, there is
space for antibiotic stewardship, cost savings and reduction
of potential spread of antibiotic resistance in orthopaedic
wards [9].
Our study has biases: (1) It is a single-centre retrospective
study, limiting the general application of the results. Although
including 342 episodes, this number might be too small to
detect differences in the outcome. Concerning substrata of
implant infections, only 86 implants were retained, and only
two witnessed a one-stage arthroplasty exchange, further
limiting the generalisability of our data. (2) Our patients had
no haemodynamic compromises. For patients in intensive
care, adequate initial empirical antibiotic coverage is crucial
and may be lifesaving. (3) Patients may have been followed
elsewhere. However, because Geneva University Hospitals
are the only public hospital in the area, and most arthroplasty
patients participate in our register, we estimate this bias as
minimal. (4) With only 29 episodes without any empirical
antibiotics at all, we cannot pronounce on the question of
whether antibiotic coverage per se would be necessary. This
question needs a much larger study population. (5) The dura-
tion of empirical therapy peaked around three days, which
should not be confounded with culture-negative therapy
throughout the course. The literature is divided on whether a
culture-negative therapy would [6] or would not be [10, 16]
associated with higher failure risk.
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